Skip to main content

Table 3 Adjusted hazard ratios (95%CI) for overall survival and recurrence-free survival by tumor CYP27A1 expression in BC-blood cohort

From: CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients

 

Model 0a

Model 1b

Model 2c

Cases

Events

CYP27A1 high vs low HR (95%CI)

Cases

Events

CYP27A1 high vs low HR (95%CI)

Cases

Events

CYP27A1 high vs low HR (95%CI)b

Follow-up period ≤ 5 years

 Overall survival

  All

808

61

1.90 (1.12–3.23)

805

59

1.40 (0.77–2.42)

804

59

1.31 (0.74–2.32)

  

P = 0.02

  

P = 0.28

  

P = 0.35

  ER+

697

41

1.84 (0.93–3.62)

695

40

1.90 (0.96–3.77)

694

40

1.93 (0.97–3.85)

  

P = 0.07

  

P = 0.06

  

P = 0.06

  ER+ and age ≥ 55 yrs

486

37

1.75 (0.84–3.63)

484

36

1.80 (0.86–3.74)

483

36

1.79 (0.85–3.75)

  

P = 0.13

  

P = 0.12

  

P = 0.12

  ER+ and age < 55 yrs

208

4

4.21 (0.56–31.78)

208

4

3.65 (0.31–42.97)

208

4

2.02 (0.13–30.70)

  

P = 0.16

  

P = 0.30

  

P = 0.61

 Recurrence-free survival

  All

808

99

1.76 (1.15–2.71)

805

97

1.32 (0.84–2.07)

804

97

1.32 (0.83–2.08)

  

P = 0.01

  

P = 0.23

  

P = 0.24

  ER+

704

72

1.50 (0.87–2.60)

702

71

1.46 (0.85–2.51)

701

71

1.51 (0.88–2.60)

  

P = 0.14

  

P = 0.17

  

P = 0.13

  ER+ and age ≥ 55 yrs

490

54

1.12 (0.58–2.17)

488

53

1.15 (0.59–2.24)

487

53

1.16 (0.60–2.26)

  

P = 0.73

  

P = 0.67

  

P = 0.66

  ER+ and age < 55 yrs

214

18

3.25 (1.20–8.76)

214

18

3.18 (1.08–9.37)

214

18

3.59 (1.15–11.20)

  

P = 0.02

  

P = 0.03

  

P = 0.03

Follow-up period > 5 years

 Overall survival

  All

570

47

1.50 (0.72–2.93)

569

46

1.14 (0.54–2.43)

568

46

1.08 (0.50–2.35)

  

P = 0.29

  

P = 0.73

  

P = 0.83

  ER+

509

40

0.96 (0.39–2.35)

508

39

0.77 (0.29–2.01)

507

39

0.79 (0.30–2.08)

  

P = 0.93

  

P = 0.59

  

P = 0.64

  ER+ and age ≥ 55 yrs

348

31

1.46 (0.43–4.92)

347

30

0.42 (0.10–1.82)

346

30

0.46 (0.11–1.98)

  

P = 0.54

  

P = 0.25

  

P = 0.30

  ER+ and age < 55 yrs

124

9

0.38 (0.08–1.70)

124

9

1.60 (0.35–7.46)

124

9

1.69 (0.33–8.73)

  

P = 0.41

  

P = 0.55

  

P = 0.53

 Recurrence-free survival

  All

527

74

1.3 (0.77–2.31)

522

75

1.19 (0.67–2.12)

521

75

1.22 (0.68–2.18)

  

P = 0.29

  

P = 0.54

  

P = 0.50

  ER+

474

67

0.83 (0.45–1.54)

470

68

1.01 (0.53–1.90)

469

68

1.05 (0.56–2.00)

  

P = 0.56

  

P = 0.99

  

P = 0.87

  ER+ and age ≥ 55 yrs

328

51

0.91 (0.44–1.91)

324

51

0.91 (0.42–1.98)

323

51

0.97 (0.44–2.10)

  

P = 0.81

  

P = 0.82

  

P = 0.93

  ER+ and age < 55 yrs

123

16

0.66 (0.21–2.08)

124

17

1.10 (0.35–3.51)

124

17

1.24 (0.36–4.20)

  

P = 0.48

  

P = 0.87

  

P = 0.73

  1. HR hazard ratio, CI confidence interval, ER+ estrogen receptor positive
  2. aModel 0: adjusted for FFPE block storage duration
  3. bModel 1: adjusted for age at diagnosis, tumor size, lymph node involvement, ER expression, tumor histological grade and FFPE block storage duration
  4. cModel 2: Model 1 + adjusted for local (radiotherapy) and systemic (endocrine and chemotherapy) treatments
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us